Sign in
Taking people in United StatesPhase 1/2

Tests CAR T cells made by a new process in children with B-cell leukemia

Tests modified immune cells made by a new process in children with leukemia.

Key facts

Who runs it
Stephan Grupp MD PhD
Where
Philadelphia, United StatesSee the site
Trial code
Registry title
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
Status
Recruiting
Phase
Phase 1/2
People taking part
115 people, planned
Started
20 Sept 2022
Expected to end
20 Sept 2029
Type of study
Interventional, 2 groups
Treatments tested
  • Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)
Record updated
26 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young adults up to 29 years old whose CD19-positive B-cell leukemia or lymphoma came back or did not respond to treatment, or did not respond to earlier cell therapy.

Age
0 to 29 years
Sex
All sexes
Disease stage
CD19-positive B-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Cohort A: relapsed or refractory disease, no earlier CAR T-cell therapy. Cohort B: poor response to earlier B cell directed engineered cell therapy.
Earlier treatment
Cohort A: no earlier CAR T-cell therapy. Cohort B: earlier B cell directed engineered cell therapy with partial or no response, a CD19-positive relapse, or early B cell recovery.
Biomarker or test result
CD19 on the cancer cells, shown by flow cytometry in bone marrow, blood, spinal fluid or tumor tissue.

Main reasons for not taking part

  • Active hepatitis B or active hepatitis C
  • HIV infection
  • Active graft-versus-host disease needing systemic therapy
  • Pregnant or nursing
  • Uncontrolled active infection

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Signed Informed Informed Consent
  • Subjects with documented CD19+ ALL or Lly:; Cohort A: Subjects with relapsed or refractory ALL or Lly who have not previously received CAR T-cell Therapy: i. 2nd or greater relapse (marrow or extramedullary) OR ii. Any relapse after allogeneic HSCT and ≥4 months from HSCT at enrollment OR iii. Refractory disease defined as having not achieved an MRD-negative (by multiparameter flow cytometry) or CSF-negative CR after ≥2 chemotherapy regimens/cycles of frontline therapy, or 1 cycle of reinduction therapy for subjects in first relapse OR iv. Newly diagnosed NCI high-risk B-ALL with induction failure, defined as a M3 bone marrow (≥25%) blasts at the end of induction chemotherapy OR v. First bone marrow relapse of B-ALL at <36 months after initial diagnosis OR vi. First or greater CNS relapse of B-ALL vii. Ineligible for allogeneic HSCT because of at least one of the following:
  • Comorbid disease 2. Other contraindications to HSCT conditioning regimen 3. Lack of suitable donor 4. Prior HSCT 5. Declines HSCT as the therapeutic option after documented discussion, with expected outcomes, and the role of HSCT with a BMT physician not a part of the study team
  • Cohort B: Subjects with poor response to prior B cell directed engineered cell therapy, defined as any one of the following: i. Partial response or no response to prior cell therapy ii. CD19+ relapse after prior cell therapy, defined as bone marrow blasts > 0.01% by multiparameter flow cytometry or evidence of extramedullary disease iii. Demonstrated early (approximately 6 months from infusion) B cell recovery suggesting loss of engineered cells
  • Subjects with prior or current history of CNS3 disease will be eligible if Central Nervous System (CNS) disease is responsive to therapy
  • Documentation of CD19 tumor expression in bone marrow, peripheral blood, cerebrospinal fluid (CSF), or tumor tissue by flow cytometry. If the subject has received CD19-directed therapy, flow cytometry should be obtained after this therapy to demonstrate CD19 expression
  • Age 0-29 years
  • Adequate organ function
  • Serum creatinine based on age/gender b. Adequate liver function: i. ALT within 5x ULN in the absence of ALL infiltration of the liver ii. Bilirubin ≤3x the upper limit of normal iii. ALT and/or bilirubin results that exceed this range are acceptable if, in the opinion of the physician-investigator (or as confirmed by liver biopsy), the abnormalities are directly related to ALL infiltration of the liver
  • Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and < Grade 3 hypoxia; DLCO ≥ 40% (corrected for anemia if necessary) if PFTs are clinically appropriate as determined by the investigator
  • Left Ventricular Shortening Fraction (LVSF) ≥28% or Ejection Fraction (LVEF) ≥45% confirmed by echocardiogram or another scan. In cases where quantitative assessment of LVSF/LVEF is not possible, a statement by the cardiologist that the ECHO shows qualitatively normal ventricular function will suffice
  • Adequate performance status defined as Lanksy or Karnofsky performance score ≥50
  • Subjects of reproductive potential must agree to use acceptable birth control methods

Who cannot take part

  • Concurrent use of systemic steroids or immunosuppression at the time of cell infusion or cell collection, or a condition, in the treating physician's opinion, that is likely to require steroid therapy or immunosuppression during collection or after infusion. Steroids for disease treatment at times other than cell collection or at the time of infusion are permitted. Use of physiologic replacement hydrocortisone or inhaled steroids is permitted as well
  • If the subject has received previous CAR T cell therapies, history of grade 3 or higher ICANS following administration of a CAR T cell product
  • Active hepatitis B or active hepatitis C
  • HIV infection
  • Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy
  • CNS disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity
  • Uncontrolled active infection
  • History of seizure disorder that requires ongoing anti-epileptic therapy
  • Subjects who are pregnant or nursing

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 0 and 29 years old?

Where in United States

  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: CART Nurse NavigatorTaking people

About the trial

What the trial wants to find out

This study will determine the safety and efficacy of moving to a second-generation manufacturing process using the CliniMACS Prodigy platform to manufacture huCART19 cells for patients with B cell Acute Lymphoblastic Leukemia (B-ALL).

The 2 groups in the trial

  • Dose Escalation ArmTreatment being tested

    The phase 1 dose escalation portion of the trial will use a standard "3+3" design to establish the recommended phase 2 dose of huCART19 cells in patients with subjects with prior treatment with CD19-directed CAR T cells. Two dose escalations of huCART19 are planned for the dose escalation phase.

    Treatment: Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)

  • Dose Expansion ArmsTreatment being tested

    If at least one dose level of the dose escalation phase is determined to be safe, the phase 2b dose expansion phase of the trial will be opened to enrollment. Subjects will receive the highest dose of huCART19 cells that were determined to be safe in the dose escalation part of the trial. 2 cohorts are planned: * Cohort A (relapsed/refractory, CAR T cell naïve) * Cohort B (prior treatment with CD19-directed CAR T cells)

    Treatment: Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Phase 1/2b Trial of Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells Manufactured Using the CliniMACS Prodigy Platform for the Treatment of Pediatric B Cell Acute Lymphoblastic Leukemia (B-ALL)
Plain-language title
Tests CAR T cells made by a new process in children with B-cell leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05480449, who can take part
Record updated
26 May 2026